These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 39160532)

  • 1. Detection and comparison of SARS-CoV-2 antibody produced in naturally infected patients and vaccinated individuals in Addis Ababa, Ethiopia: multicenter cross-sectional study.
    Bashea C; Gize A; Lejisa T; Bikila D; Zerihun B; Challa F; Melese D; Gebreyohanns A; Gorems K; Ali S; Hundie GB; Tola HH; Tsegaye W
    Virol J; 2024 Aug; 21(1):192. PubMed ID: 39160532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-SARS-CoV-2 total immunoglobulin and neutralising antibody responses in healthy blood donors throughout the COVID-19 pandemic: a longitudinal observational study.
    Gütlin Y; Albertos Torres D; Gensch A; Schlotterbeck AK; Stöger L; Heller S; Infanti L; Barut GT; Thiel V; Leuzinger K; Hirsch HH; Buser A; Egli A
    Swiss Med Wkly; 2024 Jul; 154():3408. PubMed ID: 39137369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of Anti-SARS-CoV-2-specific IgG Levels in Breast Milk after Vaccination or COVID-19 Infection.
    Temocin F; Çaycı YT; Seren C; Kuruoglu T; Atilla A; Birinci A; Tanyel E
    Am J Perinatol; 2024 May; 41(S 01):e3085-e3090. PubMed ID: 37846474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 immunity and reasons for non-vaccination among healthcare workers from eastern and northern Switzerland: results from a nested multicentre cross-sectional study.
    Albrecht S; Grässli F; Cusini A; Brucher A; Goppel S; Betschon E; Möller JC; Ortner M; Ruetti M; Stocker R; Vuichard-Gysin D; Besold U; Risch L; Von Kietzell M; Schlegel M; Vernazza P; Kuster SP; Kahlert CR; Kohler P
    Swiss Med Wkly; 2024 Apr; 154():3734. PubMed ID: 38689545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative contribution of COVID-19 vaccination and SARS-CoV-2 infection to population-level seroprevalence of SARS-CoV-2 spike antibodies in a large integrated health system.
    Chervo TC; Elkin EP; Nugent JR; Valice E; Amsden LB; Ergas IJ; Munneke JR; Flores M; Saelee GN; Hsiao CA; Schapiro JM; Quesenberry CP; Corley DA; Habel LA; Kushi LH; Skarbinski J
    PLoS One; 2024; 19(6):e0303303. PubMed ID: 38900738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maternal and Cord Anti-SARS-CoV-2-Spike IgG following COVID-19 Vaccination versus Infection during Pregnancy: A Prospective Study, Israel October 2021-March 2022.
    Abu Shqara R; Frank Wolf M; Mikhail Mustafa S; Sgayer I; Assulyn T; Abu Zraki A; Askhar Majadla N; Rechnizter H; Shehadeh M; Fleisher Sheffer V; Bordeynik-Cohen M; Yakir O; Lowenstein L; Sela E; Edelstein M; Dror AA
    Am J Perinatol; 2024 May; 41(S 01):e1935-e1943. PubMed ID: 37164317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of SARS-CoV-2 seroprevalence estimates between commercial lab serum specimens and blood donor specimens, United States, September-December 2021.
    Kao S-YZ; Nycz E; Benoit TJ; Clarke KEN; Jones JM
    Microbiol Spectr; 2024 Aug; 12(8):e0012324. PubMed ID: 38869287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Anti-SARS-CoV-2-Specific Antibody Signatures in Maternal and Infant Blood after COVID-19 Infection versus COVID-19 Vaccination during Pregnancy.
    Sabharwal V; Taglauer E; Demos R; Snyder-Cappione J; Shaik-Dasthagirisaheb YB; Parker-Kelleher S; Hunnewell J; Boateng J; Clarke K; Yuen R; Barnett ED; Wachman EM; Yarrington CD
    Am J Perinatol; 2024 May; 41(S 01):e2970-e2977. PubMed ID: 37774748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of Antibody Responses Against SARS-CoV-2 in Plasma and Saliva From Vaccinated and Infected Individuals.
    Klingler J; Lambert GS; Itri V; Liu S; Bandres JC; Enyindah-Asonye G; Liu X; Simon V; Gleason CR; Kleiner G; Chiu HP; Hung CT; Kowdle S; Amanat F; Lee B; Zolla-Pazner S; Upadhyay C; Hioe CE
    Front Immunol; 2021; 12():759688. PubMed ID: 34987505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Elecsys® Anti-SARS-CoV-2 and Elecsys® Anti-SARS-CoV-2 S antibody assays: Differentiating between vaccination and infection, and assessing long-term performance.
    Quee FA; Hogema BM; Molier M; Slot E; van den Hurk K; Zaaijer HL
    PLoS One; 2024; 19(7):e0305613. PubMed ID: 39024252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
    Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
    Front Immunol; 2021; 12():786554. PubMed ID: 35003104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine.
    Kang YM; Minn D; Lim J; Lee KD; Jo DH; Choe KW; Kim MJ; Kim JM; Kim KN
    J Korean Med Sci; 2021 Nov; 36(46):e311. PubMed ID: 34845875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants.
    Ibarrondo FJ; Hofmann C; Ali A; Ayoub P; Kohn DB; Yang OO
    mBio; 2021 Dec; 12(6):e0265621. PubMed ID: 34872349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up.
    Salehi M; Alavi Darazam I; Nematollahi A; Alimohammadi M; Pouya S; Alimohammadi R; Khajavirad N; Porgoo M; Sedghi M; Mahdi Sepahi M; Azimi M; Hosseini H; Mahmoud Hashemi S; Dehghanizadeh S; Khoddami V
    Int Immunopharmacol; 2024 Jun; 134():112192. PubMed ID: 38761778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans.
    Forgacs D; Jang H; Abreu RB; Hanley HB; Gattiker JL; Jefferson AM; Ross TM
    Front Immunol; 2021; 12():728021. PubMed ID: 34646267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seroprevalence and levels of IgG antibodies after COVID-19 infection or vaccination.
    Soeorg H; Jõgi P; Naaber P; Ottas A; Toompere K; Lutsar I
    Infect Dis (Lond); 2022 Jan; 54(1):63-71. PubMed ID: 34520315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term immune response to SARS-CoV-2 infection and vaccination in children and adolescents.
    Messiah SE; Talebi Y; Swartz MD; Sabharwal R; Han H; Bergqvist E; Kohl HW; Valerio-Shewmaker M; DeSantis SM; Yaseen A; Kelder SH; Ross J; Padilla LN; Gonzalez MO; Wu L; Lakey D; Shuford JA; Pont SJ; Boerwinkle E
    Pediatr Res; 2024 Jul; 96(2):525-534. PubMed ID: 37875728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.